FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802888891> ?p ?o ?g. }

• W2802888891 abstract "Cardiological societies recommend, in their guidelines, that patients with atrial fibrillation and an intermediate (or higher) risk of stroke and systemic embolization should be treated with oral anticoagulant drugs. For patients who do not have mitral valve stenosis or a mechanical valve prosthesis, non-vitamin-K dependent oral anticoagulants (NOAC) are preferred over vitamin K antagonists (VKA) for this purpose. It is unclear, however, whether patients with chronic kidney disease and atrial fibrillation benefit from oral anticoagulation to the same extent as those with normal kidney function. It is also unclear which of the two types of anti - coagulant drug is preferable for patients with chronic kidney disease; NOAC are, in part, renally eliminated.This review is based on pertinent publications retrieved by a selective literature search, and on international guidelines.Current evidence suggests that patients with atrial fibrillation who have chronic kidney disease with a glomerular filtration rate (GFR) above 15 mL/ min/1.73 m² should be treated with an oral anticoagulant drug if they have an at least intermediate risk of embolization, as assessed with the CHA2DS2-VASc score. For patients with advanced chronic kidney disease (GFR from 15 to 29 mL/ min/1.73 m²), however, this recommendation is based only on registry studies. For dialysis patients with atrial fibrillation, decisions whether to give oral anticoagulant drugs should be taken on an individual basis, in view of the elevated risk of hemorrhage and the unclear efficacy of such drugs in these patients. The subgroup analyses of the NOAC approval studies show that, for patients with atrial fibrillation and chronic kidney disease with a creatinine clearance of >25-30 mL/min, NOAC should be given in preference to VKA, as long as the patient does not have mitral valve stenosis or a mechanical valve prosthesis. For those whose creatinine clearance is less than 25 mL/min, the relative merits of NOAC versus VKA are still debated.The cardiological societies' recommendation that patients with atrial fibrillation should be given oral anticoagulant drugs applies to the majority of such patients who also have chronic kidney disease." @default.
• W2802888891 created "2018-05-17" @default.
• W2802888891 creator A5011285126 @default.
• W2802888891 creator A5034817908 @default.
• W2802888891 creator A5085543527 @default.
• W2802888891 date "2018-04-27" @default.
• W2802888891 modified "2023-10-16" @default.
• W2802888891 title "Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation" @default.
• W2802888891 cites W173028345 @default.
• W2802888891 cites W1913544684 @default.
• W2802888891 cites W1973002697 @default.
• W2802888891 cites W1981055539 @default.
• W2802888891 cites W1981440884 @default.
• W2802888891 cites W1982764283 @default.
• W2802888891 cites W2004592440 @default.
• W2802888891 cites W2028661943 @default.
• W2802888891 cites W2031100777 @default.
• W2802888891 cites W2050636770 @default.
• W2802888891 cites W2055586130 @default.
• W2802888891 cites W2060630424 @default.
• W2802888891 cites W2063976695 @default.
• W2802888891 cites W2073789348 @default.
• W2802888891 cites W2084790107 @default.
• W2802888891 cites W2088140015 @default.
• W2802888891 cites W2108141317 @default.
• W2802888891 cites W2121394112 @default.
• W2802888891 cites W2125970071 @default.
• W2802888891 cites W2127985968 @default.
• W2802888891 cites W2130977972 @default.
• W2802888891 cites W2131525218 @default.
• W2802888891 cites W2137138584 @default.
• W2802888891 cites W2141889414 @default.
• W2802888891 cites W2152412672 @default.
• W2802888891 cites W2152623033 @default.
• W2802888891 cites W2159193915 @default.
• W2802888891 cites W2159229357 @default.
• W2802888891 cites W2162586165 @default.
• W2802888891 cites W2165762371 @default.
• W2802888891 cites W2168044922 @default.
• W2802888891 cites W2224300218 @default.
• W2802888891 cites W2340106881 @default.
• W2802888891 cites W2401473670 @default.
• W2802888891 cites W2433454023 @default.
• W2802888891 cites W2436531740 @default.
• W2802888891 cites W2439026761 @default.
• W2802888891 cites W2509795914 @default.
• W2802888891 cites W2516919363 @default.
• W2802888891 cites W2529460814 @default.
• W2802888891 cites W2534290193 @default.
• W2802888891 cites W2561745040 @default.
• W2802888891 cites W2562241672 @default.
• W2802888891 cites W2566947560 @default.
• W2802888891 cites W2571124477 @default.
• W2802888891 cites W2596305759 @default.
• W2802888891 cites W2606922710 @default.
• W2802888891 cites W2607277152 @default.
• W2802888891 cites W2884916956 @default.
• W2802888891 cites W3004050106 @default.
• W2802888891 cites W594767912 @default.
• W2802888891 doi "https://doi.org/10.3238/arztebl.2018.0287" @default.
• W2802888891 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5974258" @default.
• W2802888891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29789105" @default.
• W2802888891 hasPublicationYear "2018" @default.
• W2802888891 type Work @default.
• W2802888891 sameAs 2802888891 @default.
• W2802888891 citedByCount "23" @default.
• W2802888891 countsByYear W28028888912018 @default.
• W2802888891 countsByYear W28028888912019 @default.
• W2802888891 countsByYear W28028888912020 @default.
• W2802888891 countsByYear W28028888912021 @default.
• W2802888891 countsByYear W28028888912022 @default.
• W2802888891 countsByYear W28028888912023 @default.
• W2802888891 crossrefType "journal-article" @default.
• W2802888891 hasAuthorship W2802888891A5011285126 @default.
• W2802888891 hasAuthorship W2802888891A5034817908 @default.
• W2802888891 hasAuthorship W2802888891A5085543527 @default.
• W2802888891 hasBestOaLocation W28028888912 @default.
• W2802888891 hasConcept C126322002 @default.
• W2802888891 hasConcept C127413603 @default.
• W2802888891 hasConcept C159641895 @default.
• W2802888891 hasConcept C164705383 @default.
• W2802888891 hasConcept C177713679 @default.
• W2802888891 hasConcept C2776301958 @default.
• W2802888891 hasConcept C2777185221 @default.
• W2802888891 hasConcept C2778205648 @default.
• W2802888891 hasConcept C2778653478 @default.
• W2802888891 hasConcept C2779161974 @default.
• W2802888891 hasConcept C2779978075 @default.
• W2802888891 hasConcept C2780645631 @default.
• W2802888891 hasConcept C71924100 @default.
• W2802888891 hasConcept C78519656 @default.
• W2802888891 hasConceptScore W2802888891C126322002 @default.
• W2802888891 hasConceptScore W2802888891C127413603 @default.
• W2802888891 hasConceptScore W2802888891C159641895 @default.
• W2802888891 hasConceptScore W2802888891C164705383 @default.
• W2802888891 hasConceptScore W2802888891C177713679 @default.
• W2802888891 hasConceptScore W2802888891C2776301958 @default.
• W2802888891 hasConceptScore W2802888891C2777185221 @default.
• W2802888891 hasConceptScore W2802888891C2778205648 @default.
• W2802888891 hasConceptScore W2802888891C2778653478 @default.

• next